R. Reshef

D. Porter, S. Luger, E. Hexner, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Baloxavir treatment of oseltamivir‐resistant influenza A/H1pdm09 in two immunocompromised patients

K. St. George, Marcus R. Pereira, R. Reshef, 2020, Transplant infectious disease : an official journal of the Transplantation Society.

Chimerism Testing in Allogeneic Hematopoietic Stem Cell Transplantation

V. Deerlin, R. Reshef, 2016 .

Posttransplant Lymphoproliferative Disorder in Solid Organ and Hematopoietic Stem Cell Transplantation.

R. Reshef, D. Tsai, S. Nagle, 2017, Clinics in chest medicine.

A profound decrease in maternal arginine uptake provokes endothelial nitration in the pregnant rat.

D. Schwartz, G. Chernin, Y. Levo, 2008, American journal of physiology. Heart and circulatory physiology.

, Ran Reshef , Tamara , in uremic rats α inhibition of PKC Rosiglitazone improves aortic arginine transport , through

I. Filip, D. Schwartz, Y. Levo, 2008 .

Rosiglitazone improves aortic arginine transport, through inhibition of PKCalpha, in uremic rats.

I. Filip, D. Schwartz, Y. Levo, 2008, American journal of physiology. Renal physiology.

Differential regulation of L-arginine transporters (cationic amino acid transporter-1 and -2) by peroxynitrite in rat mesangial cells.

D. Schwartz, G. Chernin, D. Hagin, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Peripheral blood stem cell grafts in allogeneic hematopoietic cell transplantation: It is not all about the CD34+ cell dose.

R. Reshef, 2021, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Association of HLA Polymorphisms with Post‐transplant Lymphoproliferative Disorder in Solid‐Organ Transplant Recipients

D. Heitjan, D. Porter, J. Tomaszewski, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

TRANSPLANTATION Programming of donor T cells using allogeneic d -like ligand 4 – positive dendritic cells to reduce GVHD in mice

S. Mineishi, M. Zaidi, B. Blazar, 2016 .

Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment

D. Porter, B. Levine, C. June, 2016, American journal of hematology.

Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases.

J. Christie, R. Kotloff, S. Schuster, 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.

S. Steinberg, S. Pittaluga, B. Levine, 2012, Blood.

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS

S. Schuster, A. Mato, R. Reshef, 2017, International journal of hematologic oncology.

Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.

M. Carroll, D. Porter, S. Luger, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies.

M. Norkin, W. Wood, M. Aljurf, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Utility of Next Generation Sequencing for Oncogenic Mutations in AML Patients Undergoing Allogeneic Stem Cell Transplantation Biol Blood Marrow

M. Carroll, D. Porter, Selina, 2016 .

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

S. de Vos, D. Maloney, I. Yakoub-Agha, 2021, Blood.

D. Porter, S. Luger, E. Hexner, 2016, American journal of hematology.

Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis

B. Sandmaier, M. Aljurf, R. Gale, 2016, Cancer.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

D. Porter, F. Locatelli, E. Holler, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab for PTLD of the CNS: Is It a ‘No-Brainer’?

R. Reshef, D. Tsai, 2008, Oncology Research and Treatment.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

N. Kröger, E. Holler, Y. Efebera, 2018, Blood.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

N. Kröger, F. Locatelli, E. Holler, 2017, JCI insight.

Plasmacytic post‐transplant lymphoproliferative disorder: a case series of nine patients

S. Schuster, M. Karuturi, V. Ahya, 2013, Transplant international : official journal of the European Society for Organ Transplantation.

Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease

D. Porter, A. Perl, S. Luger, 2010, Bone Marrow Transplantation.

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

E. Holler, Z. DeFilipp, Jung-Yi Lin, 2022, Blood advances.

Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study

J. Bolaños-Meade, Yi-Bin Chen, J. Hansen, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved accuracy of acute graft-versus-host disease staging among multiple centers.

Y. Efebera, S. Devine, W. Hogan, 2014, Best practice & research. Clinical haematology.

Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors.

D. Porter, S. Luger, E. Hexner, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats.

D. Schwartz, G. Chernin, Y. Levo, 2006, Kidney international.

Precision in donor selection: Identifying ideal stem-cell donors through their T cells.

R. Reshef, Adam J. Widman, 2016, Experimental hematology.

Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial.

J. Hoxie, D. Porter, E. Acosta, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cellular Immunotherapy - Highlights from TCT 2021.

P. Muranski, Jeffrey S. Miller, R. Reshef, 2021, Transplantation and cellular therapy.

HEMATOPOIESIS AND STEM CELLS Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice

Changhong Li, Yuting Gu, M. Jin, 2017 .

Standardized Semistructured Psychosocial Evaluation Before Stem Cell Transplantation Predicts Delirium After Transplant.

P. Shapiro, S. López-Pintado, M. Mapara, 2021, Journal of the Academy of Consultation-Liaison Psychiatry.

Standardized semi-structured psychosocial evaluation before hematopoietic stem cell transplantation predicts patient adherence to post-transplant regimen.

P. Shapiro, S. López-Pintado, M. Mapara, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia: No Impact of Pre-transplant Extramedullary Disease on Outcome

M. Tallman, R. Gale, T. Shea, 2015, Bone Marrow Transplantation.

Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation

D. Porter, W. Hwang, T. Miano, 2016, Bone Marrow Transplantation.

Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)

P. Riedell, F. Milletti, J. Kawashima, 2019, Blood.

Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.

M. Perales, F. Appelbaum, D. Porter, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder ★

D. Heitjan, D. Porter, L. Goldberg, 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies

M. Mapara, R. Reshef, Amer Assal, 2021, Annals of Hematology.

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder

D. Heitjan, A. Bagg, D. Porter, 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduce

N. Geller, P. Hari, D. Porter, 2019, The Lancet. Haematology.

Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.

M. Tallman, R. Gale, M. Flowers, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.

G. Salles, S. de Vos, D. Maloney, 2021, The Lancet. Oncology.

TGM4: an immunogenic prostate-restricted antigen

C. Drake, Uri Laserson, E. Antonarakis, 2021, Journal for ImmunoTherapy of Cancer.

Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature.

D. Porter, C. Pasin, A. Yates, 2021, Transplantation and cellular therapy.

Fertility Concerns and Access to Care for Stem Cell Transplant Candidates with Sickle Cell Disease.

M. Mapara, R. Reshef, Adrienne D. Mishkin, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Iatrogenic Infertility After Curative Stem Cell Transplantation in Patients With Sickle Cell Disease

M. Mapara, R. Reshef, Adrienne D. Mishkin, 2018, Annals of Internal Medicine.

Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy.

Y. Ben-Arieh, R. Reshef, N. Haim, 1995, Leukemia & lymphoma.

Shaping the Molecular Landscape of Posttransplantation Lymphoproliferative Disorders

R. Reshef, D. Tsai, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity

Bethany Moore, Shan He, Changhong Li, 2017, Nature Communications.

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice.

Yuting Gu, M. Jin, Yanyun Zhang, 2017, Blood.

Prevention of graft-versus-host disease.

R. Reshef, 2012, Clinical advances in hematology & oncology : H&O.

Antibiotic exposure, not alloreactivity, is the major driver of microbiome changes in hematopoietic cell transplantation: Antibiotics in auto and allo transplant.

Heekuk Park, A. Uhlemann, M. Mapara, 2021, Transplantation and cellular therapy.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

J. Hoxie, D. Porter, R. H. Moy, 2017, Blood.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide.

Shannon R. McCurdy, M. Norkin, M. Perales, 2018, Blood advances.

The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation

S. Mineishi, Zhenjiang Bai, Yanyun Zhang, 2016, The Journal of Immunology.

High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT

D. Heitjan, D. Porter, S. Luger, 2012, Bone Marrow Transplantation.

Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.

R. Vij, M. Aljurf, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis.

R. Soiffer, M. Grunwald, N. Ghosh, 2021, Blood.

Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.

D. Porter, T. Miano, R. Vonderheide, 2015, The Journal of antimicrobial chemotherapy.

GVHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes

M. Aljurf, I. Lewis, R. Gale, 2016, Bone Marrow Transplantation.

Evaluation of elafin as a prognostic biomarker in acute graft-versus-host disease.

S. Grupp, Yi-Bin Chen, Z. DeFilipp, 2021, Transplantation and cellular therapy.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.

E. Holler, Yi-Bin Chen, Z. DeFilipp, 2020, Blood advances.

Disease Risk and GVHD Biomarkers Can Stratify Patients For Risk of Relapse and Non-Relapse Mortality Post Hematopoietic Cell Transplant

N. Kröger, Yi-Bin Chen, M. Qayed, 2020, Leukemia.

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease.

S. Grupp, Z. DeFilipp, K. Sigel, 2019, Blood advances.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

J. Ritz, P. Westervelt, J. Dipersio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.

J. Hoxie, D. Heitjan, D. Porter, 2012, The New England journal of medicine.

Reduced-intensity conditioned allogeneic SCT in adults with AML

D. Porter, R. Reshef, David L Porter, 2015, Bone Marrow Transplantation.

Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.

D. Porter, R. Mick, S. Luger, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated

S. Nikiforow, H. Nakasone, J. Pidala, 2018, Haematologica.

Functional Unresponsiveness and Replicative Senescence of Myeloid Leukemia Antigen–specific CD8+ T Cells After Allogeneic Stem Cell Transplantation

F. Johnson, D. Porter, R. Vonderheide, 2009, Clinical Cancer Research.

Variable selection methods for predicting clinical outcomes following allogeneic hematopoietic cell transplantation

R. H. Moy, C. Pasin, A. Yates, 2021, Scientific Reports.

COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

G. Morgan, S. Jagannath, Y. Taur, 2020, Blood cancer discovery.

Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation

V. Bhatt, Stephanie J. Lee, B. Shaw, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24).

G. Salles, D. Maloney, V. Plaks, 2021 .

Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).

G. Salles, D. Maloney, V. Plaks, 2020 .

Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.

J. Cortes, M. Aljurf, M. Tallman, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

T. Kambayashi, A. Fesnak, D. Raulet, 2015, Blood.

TRANSPLANTATION NKG 2 D expression by CD 8 1 T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT

T. Kambayashi, A. Fesnak, D. Raulet, 2015 .

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

J. Mehta, M. Perales, N. Saba, 2019, Clinical Cancer Research.

Prevention of graft versus host disease with Hematopoietic CellTransplantation with Reduced Intensity Conditioning—a comparison of threeprophylaxis regimens (tacrolimus/mycophenolate mofetil/cyclophosphamide,tacrolimus/methotrexate/bortezomib or tacrolimus/methotrexate/maraviroc) versustacrolimus/me

N. Geller, P. Hari, M. Pasquini, 2019 .

Allogeneic CAR-T PBCAR0191 with Intensified Lymphodepletion Is Highly Active in Patients with Relapsed/Refractory B-Cell Malignancies

C. Jacobson, N. Jain, L. Akard, 2021, Blood.

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.

C. Jacobson, N. Jain, L. Akard, 2021 .

Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.

R. Reshef, R. Bansal, 2020, Blood reviews.

Inhibition of Lymphocyte Trafficking Using a CCR5 Antagonist – Final Results of a Phase I/II Study

J. Hoxie, D. Heitjan, D. Porter, 2011 .

Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy

L. Vercellino, L. Schwartz, L. Dercle, 2021, Frontiers in Oncology.

D. Porter, S. Luger, E. Hexner, 2016, American journal of hematology.

Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study

M. Perales, S. Putta, W. Saber, 2022, Transplantation and cellular therapy.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, J. Klein, 2015, Biology of Blood and Marrow Transplantation.

Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis.

D. Porter, R. Vonderheide, R. Reshef, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia

M. Mapara, J. Jurcic, R. Reshef, 2020, Leukemia & lymphoma.

Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

M. Perales, Richard J. Jones, Y. Efebera, 2022, Blood.

Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.

D. Porter, B. Levine, C. June, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effective treatment of low risk acute GVHD with itacitinib monotherapy.

Z. DeFilipp, A. Alousi, M. Qayed, 2022, Blood.

Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease

M. Mapara, R. Reshef, Amer Assal, 2020, Transplant infectious disease : an official journal of the Transplantation Society.

Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD

G. Sayer, N. Uriel, J. Raikhelkar, 2022, JACC. CardioOncology.

Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study

M. Aljurf, J. Szer, R. Gale, 2020 .

Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study

J. Hoxie, D. Porter, E. Acosta, 2017 .

The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013

A. Shaked, R. Bloom, L. Goldberg, 2018, American journal of hematology.

Arginine uptake is attenuated, through post-translational regulation of cationic amino acid transporter-1, in hyperlipidemic rats.

D. Schwartz, G. Chernin, Y. Levo, 2007, Atherosclerosis.

Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy

S. Dave, G. Bhagat, F. Hernandez-Ilizaliturri, 2021, Blood.

ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)

P. McCarthy, S. Neelapu, O. Oluwole, 2020 .

Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder

S. Nikiforow, R. Baiocchi, K. Mahadeo, 2017 .

What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak

M. Yin, A. Uhlemann, J. Bathon, 2021, PloS one.

Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity

J. Issa, B. Moore, Changhong Li, 2017, Nature Communications.

Maintenance tyrosine kinase inhibitors following allo-HCT for chronic myeloid leukemia: A CIBMTR Study.

M. Aljurf, J. Szer, R. Gale, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation

M. Norkin, R. Vij, M. Horowitz, 2018, Bone Marrow Transplantation.

Comparison of Gvhd Biomarker Algorithms for Predicting Lethal Gvhd and Non-Relapse Mortality

E. Holler, Yi-Bin Chen, Jung-Yi Lin, 2019, Biology of Blood and Marrow Transplantation.

Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients

R. Mick, S. Luger, R. Vonderheide, 2013 .

Acute Gvhd Diagnosis and Adjudication in a Multicenter Trial – a Report from the BMT CTN 1202 Biorepository Study

Yi-Bin Chen, J. Hansen, W. Saber, 2019, Biology of Blood and Marrow Transplantation.

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

K. Mahadeo, S. Choquet, P. Stiff, 2021, Blood.

Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Stem-Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies

M. Mapara, R. Reshef, Amer Assal, 2017 .

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

R. Varadhan, C. Huff, M. Perales, 2023, The New England journal of medicine.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

N. Kröger, F. Locatelli, E. Holler, 2018, JCI insight.

Improved serologic responses to DTaP over Tdap vaccination in adult hematopoietic cell transplant recipients

M. Mapara, R. Reshef, Amer Assal, 2023, European journal of haematology.

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

S. Neelapu, O. Oluwole, A. Kilcoyne, 2022, Blood.

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

J. Ritz, P. Westervelt, J. Dipersio, 2016 .

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

S. Grupp, E. Holler, Z. DeFilipp, 2023, Blood advances.

EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival

K. Olthoff, A. Morgans, R. Bloom, 2008 .

IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)

G. Salles, D. Maloney, V. Plaks, 2020 .

African tick bite fever in a returned traveler.

Y. Levo, R. Reshef, M. Giladi, 2007, The Israel Medical Association journal : IMAJ.

NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.

T. Kambayashi, A. Fesnak, D. Raulet, 2015, Blood.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis.

J. Hoxie, D. Porter, R. H. Moy, 2017, Blood.

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.

M. Perales, Richard J. Jones, J. Bolaños-Meade, 2023, The New England journal of medicine.

The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen.

S. Montoto, Sonali M. Smith, D. Maloney, 2015, Biology of Blood and Marrow Transplantation.

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

R. Vij, P. Hari, N. Raje, 2022, Blood.

High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning.

D. Porter, R. Mick, T. Kambayashi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.